Chris Hyde

Summary

Publications

  1. doi request reprint Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model
    Christopher Hyde
    PCMD, University of Exeter, PenTAG, Veysey Building Salmon Pool Lane, Exeter, Devon EX2 4SG, UK
    Age Ageing 42:14-20. 2013
  2. pmc The acute management of trauma hemorrhage: a systematic review of randomized controlled trials
    Nicola Curry
    NHS Blood and Transplant, Oxford Radcliffe Hospitals NHS Trust and University of Oxford, Headley Way, Oxford, OX3 9BQ, UK
    Crit Care 15:R92. 2011
  3. doi request reprint Evolution of a cost-utility model of donepezil for Alzheimer's disease
    Jaime L Peters
    PenTAG, University of Exeter, UK
    Int J Technol Assess Health Care 29:147-54. 2013
  4. doi request reprint Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Medical School, University of Exeter, Exeter, UK
    Value Health 16:288-96. 2013

Collaborators

  • Martin Hoyle
  • Jaime L Peters
  • Nicola Curry
  • Rob Anderson
  • Simon Stanworth
  • Karim Brohi
  • Carolyn Doree
  • Sally Hopewell

Detail Information

Publications4

  1. doi request reprint Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model
    Christopher Hyde
    PCMD, University of Exeter, PenTAG, Veysey Building Salmon Pool Lane, Exeter, Devon EX2 4SG, UK
    Age Ageing 42:14-20. 2013
    ..Introduction: in 2007 the National Institute of Health and Clinical Excellence (NICE) restricted the use of acetylcholinesterase inhibitors and memantine...
  2. pmc The acute management of trauma hemorrhage: a systematic review of randomized controlled trials
    Nicola Curry
    NHS Blood and Transplant, Oxford Radcliffe Hospitals NHS Trust and University of Oxford, Headley Way, Oxford, OX3 9BQ, UK
    Crit Care 15:R92. 2011
    ....
  3. doi request reprint Evolution of a cost-utility model of donepezil for Alzheimer's disease
    Jaime L Peters
    PenTAG, University of Exeter, UK
    Int J Technol Assess Health Care 29:147-54. 2013
    ....
  4. doi request reprint Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Medical School, University of Exeter, Exeter, UK
    Value Health 16:288-96. 2013
    ....